Compounding Drug Pricing Pharmaceutical Companies 
Drug Patent Watch
DECEMBER 18, 2024
Jane Smith, a patent attorney specializing in pharmaceuticals, advises: “File early and file often. Each stage of drug development can potentially yield patentable inventions. From initial compound discovery to formulation improvements, every step offers opportunities for patent protection.”
pharmaphorum
JUNE 12, 2025
Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 23, 2025
This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs. Based on this ruling, 505(b)(2) drugs that are not therapeutically interchangeable should be considered sole-source drugs.
STAT
APRIL 23, 2025
… Four months ago, a small pharmaceuticals company bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150% , STAT says. European pharmaceutical bosses have called on the European Union to increase drug prices toward the much higher levels paid by the U.S.,
Pharmacy Times
AUGUST 5, 2025
Pharmaceutical companies benefit from extended R&D tax incentives and reshoring manufacturing, favoring long-term investment. Critics argue the bill prioritizes pharmaceutical profits, reduces Medicare's negotiation power, and increases inequality in healthcare access.
Pharmaceutical Technology
JUNE 27, 2025
Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 receptor agonists (GLP-1RA), due to the emergence of compounded alternatives in the past few years.
Pharma Marketing Network
APRIL 17, 2025
For many pharmaceutical companies in 2025, the answer is clear: pivot aggressively toward digital. With geopolitical volatility sparking new tariff threats and mounting legislative scrutiny over pharmaceutical television ads, pharma digital ad spend is experiencing a noticeable surge.
Expert insights. Personalized for you.
Let's personalize your content